Tandem Diabetes Care, Inc. announced the publication of positive results from its pivotal trial of Control-IQ+ automated insulin delivery (AID) technology in people with type 2 diabetes in the New England Journal of Medicine. The study demonstrated significant improvements in time in range and hemoglobin A1c for participants using the Control-IQ+ system. This publication provides strong clinical validation for the technology's effectiveness in this patient population.
Additional findings from the trial were presented during a symposium at the 18th International Conference on Advanced Technologies & Treatments for Diabetes in Amsterdam, the Netherlands. The trial results reinforce the benefits of AID for adults with type 2 diabetes, a group that has historically had limited options for advanced diabetes management.
This scientific validation supports Tandem's mission to expand access to its AID technology. The positive outcomes from a large-scale, randomized, controlled study are crucial for demonstrating the clinical utility and potential for improved health outcomes for individuals with type 2 diabetes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.